## VE-Cadherin antibody [BV9]

## Cat. No. GTX54426

Host	Mouse
Clonality	Monoclonal
lsotype	lgG2a
Applications	WB, ICC/IF, IHC-Fr, FCM, IP, ELISA, Neutralizing/Inhibition
Reactivity	Human

Package

50 µg

## Applications

## **Application Note**

\*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
ICC/IF	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
IP	Assay dependent
ELISA	Assay dependent
Neutralizing/Inhibition	Assay dependent

Note : A reduced sample treatment and 7.5% SDS-Page was used.

Cells on coverslips were fixed with 3% paraformaldehyde and permeabilized with 0.5% Triton X-100 before incubation with antibody BV9. Acetone fixed sections were blocked with horse serum and incubated with antibody BV9 for 30 minutes.

Antibody BV9 can function as coat and detector.

Functions as an antagonist. The antibody was functionally tested by adding 10-50 µg/ml antibody BV9 to cell culture. It blocks VE-cadherin causing a redistribution of VE-cadherin away from intracellular junctions.

Not tested in other applications.

Calculated MW	88 kDa. ( <u>Note</u> )
Product Note	This antibody stains the extracellular domain of VE-cadherin. The monoclonal antibody BV9 binds to the extracellular domain (EC3-EC4) of human VE-cadherin (vascular endothelial cadherin).

Properties	
Form	Liquid
Buffer	Filter-sterilized PBS, 0.1% BSA
Preservative	No preservative
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 06 / 17 Page 1 of 2



Concentration	100 µg/ml (Please refer to the vial label for the specific concentration.)
Purification	Protein G purified
Endotoxin	< 24 EU/mg (Determined by LAL assay)
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 06 / 17 Page 2 of 2